Lv1
20 积分 2023-11-03 加入
HAEMORRHAGIC SHOCK SECONDARY TO AORTO-ENTERIC FISTULA AFTER TREATMENT WITH BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER CASE REPORT AND REVIEW OF THE LITERATURE
5天前
已关闭
Evaluation of clinical decision support systems in oncology: An updated systematic review
15天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
15天前
已完结
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
24天前
已完结
BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
24天前
已完结
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial
24天前
已完结
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
1个月前
已完结
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
1个月前
已完结
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
1个月前
已完结
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma
1个月前
已完结
皖公网安备34019202002308
